Additional Effect of Intrapulmonary Percussive Ventilation (IPV) on Re
The Additional Effect of Intrapulmonary Percussive Ventilation (IPV) on Respiration in People With Multiple Sclerosis (MS).
What it found
The trial ended early for another reason (see below).
Reason given: Due to COVID-19 situation IPV is no longer allowed in the center
This trial finished 6 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Intrapulmonary percussive ventilation (IPV)
Given to everyone in the trial
- Active breathing training
What it measured
Main measures
Change in breathing force
pre- post (3 weeks) (some participants also at 4 weeks)
Other measures (7)
Change in Pulmonary Dysfunction Index (PDI)
pre- post (3 weeks) (some participants also at 4 weeks)
Change in Maximum Phonation time (MFT)
pre- post (3 weeks) (some participants also at 4 weeks)
Change in Voice Handicap Index (VHI-10)
pre- post (3 weeks) (some participants also at 4 weeks)
Change in Vital Capacity (VC)
pre- post (3 weeks) (some participants also at 4 weeks)
Change in Maximum Inspiratory Pressure (MIP)
pre- post (3 weeks) (some participants also at 4 weeks)
Physical functionChange in Maximum Expiratory Pressure (MEP)
pre- post (3 weeks) (some participants also at 4 weeks)
Nerve conduction testsChange in Visual Analogue Scale (VAS) for fatigue
pre- post (3 weeks) (some participants also at 4 weeks)
Fatigue
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
* diagnosis MS * inpatient in the National Multiple Sclerosis Center Melsbroek for at least 3 weeks in the period Jan-Dec 2020 * adequate lip closure * adequate cognitive functioning (MMSE>26/30 \& clinical observation) * Peak Expiratory Flow (PEF) with a cut off score of 80% or lower
Exclusion criteria
* IPV or other breathing treatment of more than 1x/week within 3 months prior to study participation * MS relapse within 3 months prior to study participation * asthma or Chronic Obstructive Pulmonary Disease (COPD) * infection of lower respiratory tract within 6 weeks prior to study participation * infection of upper respiratory tract within 2 weeks prior to study participation
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This study aims to investigate whether intrapulmonary percussive ventilation (IPV) in combination with active breathing exercises using the flow-based incentive spirometer (Inspirix) has a positive effect on the respiratory values in people with multiple sclerosis (MS).
Loading reviews and guidelines…
History
Started
Jan 2020
Main results due
Jul 2020
Finished
Jul 2020